David Halpin
- Comorbidities at time of COPD diagnosisBy David Price, David Halpin, Robert Winter, Susan Hill, Eric Bateman, Daryl Freeman, Dermot Ryan, Matthew Kearney, Kevin Holton, Annie Burden, Julie von Ziegenweidt, Laurence Mascarenhas, Alison Chisholm and Rupert JonesDavid PriceDavid Halpin3Royal Devon & Exeter Hospital, NHS Foundation Trust, Exeter, United KingdomRobert WinterSusan Hill4Respiratory Programme, Department of Health, London, United KingdomEric Bateman6Respiratory Medicine, University of Cape Town, Cape Town, South AfricaDaryl Freeman7General Practice with Specialist Interest in Respiratory Medicine, Sheringham Medical Practice, Norfolk, United KingdomDermot Ryan8General Practice with Specialist Interest in Respiratory Medicine, Woodbrook Medical Centre, Loughborough, United KingdomMatthew KearneyKevin Holton4Respiratory Programme, Department of Health, London, United KingdomAnnie Burden2Observational Research, Research in Real Life, Norwich, United KingdomJulie von Ziegenweidt2Observational Research, Research in Real Life, Norwich, United KingdomLaurence Mascarenhas2Observational Research, Research in Real Life, Norwich, United KingdomAlison Chisholm2Observational Research, Research in Real Life, Norwich, United KingdomRupert Jones10Peninsula Medical School, University of Plymouth, Plymouth, United Kingdom
- Missed opportunities to diagnose COPDBy David Price, David Halpin, Robert Winter, Susan L. Hill, Eric Bateman, Daryl Freeman, Dermot Ryan, Matthew Kearney, Kevin Holton, Annie Burden, Julie von Ziegenweidt, Laurence Mascarenhas, Alison Chisholm and Rupert JonesDavid PriceDavid Halpin3Royal Devon & Exeter Hospital, NHS Foundation Trust, Exeter, United KingdomRobert WinterSusan L. Hill4Respiratory Programme, Department of Health, London, United KingdomEric Bateman6Respiratory Medicine, University of Cape Town, Cape Town, South AfricaDaryl Freeman7General Practice with Specialist Interest in Respiratory Medicine, Sheringham Medical Practice, Norfolk, United KingdomDermot Ryan8General Practice with Specialist Interest in Respiratory Medicine, Woodbrook Medical Centre, Loughborough, United KingdomMatthew KearneyKevin Holton4Respiratory Programme, Department of Health, London, United KingdomAnnie Burden2Observational Research, Research in Real Life, Norwich, United KingdomJulie von Ziegenweidt2Observational Research, Research in Real Life, Norwich, United KingdomLaurence Mascarenhas2Observational Research, Research in Real Life, Norwich, United KingdomAlison Chisholm2Observational Research, Research in Real Life, Norwich, United KingdomRupert Jones10Peninsula Medical School, University of Plymouth, Plymouth, United Kingdom
- Effectiveness of tiotropium in low-risk patients according to new GOLD severity gradingBy David Halpin, Marc Decramer, Bart Celli, Antonio Martín, Inge Leimer, Norbert Metzdorf and Donald TashkinDavid Halpin1Respiratory Medicine, Royal Devon and Exeter Hospital, Exeter, United KingdomMarc Decramer2Respiratory Division, University of Leuven, BelgiumBart Celli3Pulmonary Division, Brigham and Women's Hospital, Boston, MA, United StatesAntonio Martín4Allergy and Respiratory Department, Pfizer Inc, New York, NY, United StatesInge Leimer5Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GermanyNorbert Metzdorf5Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GermanyDonald Tashkin6Dept of Medicine, David Geffen School of Medicine, Los Angeles, CA, United States
- Omalizumab improves lung function in severe persistent allergic (IgE-mediated) asthma patients: Pooled data from 5 UK centresBy Matthew Masoli, Beverley Castell, David Halpin, Chervonne Chamberlain, Robert Stone, Rahul Shrimanker, Lee Dobson, Kelly Cutland, Jay Suntharalingam, Rachel Carver and Ismail KasujeeMatthew Masoli1Chest Clinic, Derriford Hospital, Plymouth, Devon, United KingdomBeverley Castell1Chest Clinic, Derriford Hospital, Plymouth, Devon, United KingdomDavid Halpin2Respiratory Medicine, Royal Devon and Exeter Hospital, Exeter, Devon, United KingdomChervonne Chamberlain2Respiratory Medicine, Royal Devon and Exeter Hospital, Exeter, Devon, United KingdomRobert Stone3Respiratory Medicine, Musgrove Park Hospital, Taunton, Somerset, United KingdomRahul Shrimanker3Respiratory Medicine, Musgrove Park Hospital, Taunton, Somerset, United KingdomLee Dobson4Respiratory Medicine, Torbay Hospital, Torbay, Devon, United KingdomKelly Cutland4Respiratory Medicine, Torbay Hospital, Torbay, Devon, United KingdomJay Suntharalingam5Respiratory Medicine, Royal United Bath Hospital, Bath, Somerset, United KingdomRachel Carver5Respiratory Medicine, Royal United Bath Hospital, Bath, Somerset, United KingdomIsmail Kasujee6Respiratory Medicine, Novartis Pharmaceuticals UK Limited, Frimley/Camberley, Surrey, United Kingdom
- Impact of a single chronic obstructive pulmonary disease (COPD) exacerbation on lung function decline: Analysis of UPLIFT®By David Halpin, Marc Decramer, Bart Celli, Antonio Martín, Inge Leimer, Norbert Metzdorf and Donald TashkinDavid Halpin1Respiratory Medicine, Royal Devon and Exeter Hospital, Exeter, United KingdomMarc Decramer2Respiratory Division, University of Leuven, BelgiumBart Celli3Pulmonary Division, Brigham and Women's Hospital, Boston, MA, United StatesAntonio Martín4Allergy and Respiratory Department, Pfizer Inc., New York, NY, United StatesInge Leimer5Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GermanyNorbert Metzdorf5Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GermanyDonald Tashkin6Dept of Medicine, David Geffen School of Medicine, Los Angeles, CA, United States
- Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthmaBy David Halpin, Eric Bateman, Pierluigi Paggiaro, Eugene Bleecker, Michael Engel, Petra Moroni-Zentgraf, Hendrik Schmidt and Huib KerstjensDavid Halpin1Respiratory Medicine, Royal Devon & Exeter Hospital, Exeter, United KingdomEric Bateman2Department of Medicine, University of Cape Town, Cape Town, South AfricaPierluigi Paggiaro3Cardio-Thoracic and Vascular Department, University of Pisa, Pisa, ItalyEugene Bleecker4Center for Genomics and Personalized Medicine, Wake Forest School of Medicine, Winston-Salem, NC,Michael Engel5TA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, GermanyPetra Moroni-Zentgraf5TA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, GermanyHendrik Schmidt6Global Biometrics and Clinical Applications, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, GermanyHuib Kerstjens7Department of Pulmonary Medicine, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
- LATE-BREAKING ABSTRACT: Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levelsBy Peter Calverley, Christoph Hallmann, Norbert Metzdorf, Lars Grnke, Achim Mueller and David HalpinPeter Calverley1Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United KingdomChristoph Hallmann2Respiratory Medicine, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GermanyNorbert Metzdorf2Respiratory Medicine, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GermanyLars Grnke2Respiratory Medicine, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GermanyAchim Mueller2Respiratory Medicine, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GermanyDavid Halpin3Respiratory Medicine, Royal Devon & Exeter Hospital, Exeter, United Kingdom
- Eligibility of patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapyBy David Halpin, David B. Price and Marjan KerkhofDavid Halpin1Department of Respiratory Medicine, Royal Devon & Exeter Hospital, Exeter, United KingdomDavid B. Price2Center of Academic Primary Care, University of Aberdeen, Aberdeen, United Kingdom3Research in Real Life Ltd, (RiRL), Singapore, SingaporeMarjan Kerkhof4Research in Real Life Ltd, (RiRL), Cambridge, United Kingdom
- A review of national guidelines for management of COPD in EuropeBy Marc Miravitlles, Claus Vogelmeier, Nicolas Roche, David Halpin, João Cardoso, Alexander G. Chuchalin, Hannu Kankaanranta, Thomas Sandström, Paweł Śliwiński, Jaromir Zatloukal and Francesco BlasiArticle | Published in 2016 in European Respiratory JournalMarc Miravitlles1Pneumology Dept, University Hospital Vall d'Hebron, Ciber de Enfermedades Respiratorias (CIBERES), Barcelona, SpainClaus Vogelmeier2Dept of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, German Center for Lung Research (DZL), Marburg, GermanyNicolas Roche3Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Cochin, University Paris Descartes (EA2511), Paris, FranceDavid Halpin4Royal Devon and Exeter Hospital, Exeter, UKJoão Cardoso5Hospital de Santa Marta, Centro Hospitalar de Lisboa Central, Universidade Nova de Lisboa, Lisbon, PortugalAlexander G. Chuchalin6Institute of Pulmonology, Federal Medical and Biological Agency, Moscow, RussiaHannu Kankaanranta7Dept of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland8Dept of Respiratory Medicine, University of Tampere, Tampere, FinlandThomas Sandström9Department of Public Health and Clinical Medicine, Medicine Unit, Umeå University, Umeå, SwedenPaweł Śliwiński102nd Department of Respiratory Medicine, Institute of Tuberculosis and Lung Diseases, Warsaw, PolandJaromir Zatloukal11Dept of Respiratory Medicine, University Hospital Olomouc, Olomouc, Czech RepublicFrancesco Blasi12Dept of Pathophysiology and Transplantation, Università degli Studi di Milano, IRCCS Fondazione Ospedale Maggiore Policlinico Cà Granda, Milan, Italy
- A review of national guidelines for management of COPD in EuropeBy Marc Miravitlles, Claus Vogelmeier, Nicolas Roche, David Halpin, João Cardoso, Alexander G. Chuchalin, Hannu Kankaanranta, Thomas Sandström, Paweł Śliwiński, Jaromir Zatloukal and Francesco BlasiMarc Miravitlles1Pneumology Dept, University Hospital Vall d'Hebron, Ciber de Enfermedades Respiratorias (CIBERES), Barcelona, SpainClaus Vogelmeier2Dept of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, German Center for Lung Research (DZL), Marburg, GermanyNicolas Roche3Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Cochin, University Paris Descartes (EA2511), Paris, FranceDavid Halpin4Royal Devon and Exeter Hospital, Exeter, UKJoão Cardoso5Hospital de Santa Marta, Centro Hospitalar de Lisboa Central, Universidade Nova de Lisboa, Lisbon, PortugalAlexander G. Chuchalin6Institute of Pulmonology, Federal Medical and Biological Agency, Moscow, RussiaHannu Kankaanranta7Dept of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland8Dept of Respiratory Medicine, University of Tampere, Tampere, FinlandThomas Sandström9Department of Public Health and Clinical Medicine, Medicine Unit, Umeå University, Umeå, SwedenPaweł Śliwiński102nd Department of Respiratory Medicine, Institute of Tuberculosis and Lung Diseases, Warsaw, PolandJaromir Zatloukal11Dept of Respiratory Medicine, University Hospital Olomouc, Olomouc, Czech RepublicFrancesco Blasi12Dept of Pathophysiology and Transplantation, Università degli Studi di Milano, IRCCS Fondazione Ospedale Maggiore Policlinico Cà Granda, Milan, Italy
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.